Avanos Medical (AVNS)
(Delayed Data from NYSE)
$24.14 USD
-0.55 (-2.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $24.14 0.00 (0.00%) 7:06 PM ET
2-Buy of 5 2
B Value D Growth D Momentum C VGM
Income Statements
Fiscal Year end for AVANOS MEDICAL, INC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 673 | 820 | 745 | 715 | 698 |
Cost Of Goods | 294 | 370 | 380 | 342 | 295 |
Gross Profit | 380 | 450 | 364 | 373 | 402 |
Selling & Adminstrative & Depr. & Amort Expenses | 376 | 376 | 355 | 419 | 458 |
Income After Depreciation & Amortization | 4 | 74 | 9 | -46 | -56 |
Non-Operating Income | 3 | 1 | 0 | 1 | 7 |
Interest Expense | 15 | 10 | 3 | 16 | 15 |
Pretax Income | -8 | 65 | 6 | -61 | -64 |
Income Taxes | 2 | 15 | 1 | -33 | -18 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | 51 | 5 | -27 | -46 |
Extras & Discontinued Operations | -52 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -62 | 51 | 5 | -27 | -46 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 50 | 122 | 47 | -3 | -19 |
Depreciation & Amortization (Cash Flow) | 46 | 48 | 38 | 43 | 37 |
Income After Depreciation & Amortization | 4 | 74 | 9 | -46 | -56 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 46.60 | 47.30 | 48.60 | 47.80 | 47.60 |
Diluted EPS Before Non-Recurring Items | 1.03 | 1.65 | 1.15 | 0.79 | 1.07 |
Diluted Net EPS (GAAP) | -1.32 | 1.07 | 0.11 | -0.57 | -0.96 |
Fiscal Year end for AVANOS MEDICAL, INC falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 171.70 | 166.10 | 140.90 | 171.30 | 169.40 |
Cost Of Goods | 76.10 | 71.30 | 59.00 | 75.80 | 71.60 |
Gross Profit | 95.60 | 94.80 | 81.90 | 95.50 | 97.80 |
SG&A, R&D, and Dept/Amort Expenses | 89.30 | 90.80 | 79.40 | 94.30 | 99.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 6.30 | 4.00 | 2.50 | 1.20 | -2.10 |
Non-Operating Income | 3.00 | 0.60 | 1.00 | 0.90 | 0.50 |
Interest Expense | 3.10 | 3.10 | 3.30 | 4.70 | 3.50 |
Pretax Income | 6.20 | 1.50 | 0.20 | -2.60 | -5.10 |
Income Taxes | 1.90 | 1.00 | -3.50 | 6.20 | -0.80 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 4.30 | 0.50 | 3.70 | -8.80 | -4.30 |
Extras & Discontinued Operations | -2.50 | -1.40 | 6.80 | 5.10 | -63.80 |
Net Income (GAAP) | 1.80 | -0.90 | 10.50 | -3.70 | -68.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 46.30 | 46.70 | 46.60 | 46.80 | 46.80 |
Diluted EPS Before Non-Recurring Items | 0.34 | 0.22 | 0.36 | 0.30 | 0.24 |
Diluted Net EPS (GAAP) | 0.04 | -0.02 | 0.23 | -0.08 | -1.46 |